These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38962551)

  • 1. The Combination of Methionine Restriction and Docetaxel Synergistically Arrests Androgen-independent Prostate Cancer But Not Normal Cells.
    Mizuta K; Mori R; Han Q; Morinaga S; Sato M; Kang BM; Bouvet M; Tome Y; Nishida K; Hoffman RM
    Cancer Diagn Progn; 2024; 4(4):402-407. PubMed ID: 38962551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of
    Aoki Y; Kubota Y; Han Q; Masaki N; Obara K; Bouvet M; Chawla SP; Tome Y; Nishida K; Hoffman RM
    Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):679-685. PubMed ID: 38035708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Aug; 44(8):3261-3268. PubMed ID: 39060039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
    Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM
    Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts.
    Morinaga S; Han Q; Kubota Y; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Jun; 44(6):2359-2367. PubMed ID: 38821601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer.
    Sato M; Han Q; Kubota Y; Baranov A; Ardjmand D; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM
    Anticancer Res; 2024 Jan; 44(1):31-35. PubMed ID: 38159986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy of Rapamycin and Methioninase on Colorectal Cancer Cells Requires Simultaneous and Not Sequential Administration: Implications for mTOR Inhibition.
    Ardjmand D; Sato M; Han Q; Kubota Y; Mizuta K; Morinaga S; Hoffman RM
    Cancer Diagn Progn; 2024; 4(4):396-401. PubMed ID: 38962555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3777-3783. PubMed ID: 39197933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts.
    Morinaga S; Han Q; Kubota Y; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Hoffman RM
    Anticancer Res; 2024 Mar; 44(3):921-928. PubMed ID: 38423656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3785-3791. PubMed ID: 39197928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
    Kubota Y; Han Q; Masaki N; Hozumi C; Hamada K; Aoki Y; Obara K; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 Dec; 42(12):5819-5823. PubMed ID: 36456116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic Drug.
    Choobin BB; Kubota Y; Han Q; Ardjmand D; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Diagn Progn; 2023; 3(6):655-659. PubMed ID: 37927805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.
    Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM
    Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment.
    Kubota Y; Han Q; Aoki Y; Masaki N; Obara K; Hamada K; Hozumi C; Wong ACW; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Diagn Progn; 2023; 3(3):272-281. PubMed ID: 37168964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer.
    Miyake M; Miyake K; Han Q; Igarashi K; Kawaguchi K; Barangi M; Kiyuna T; Sugisawa N; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Bouvet M; Endo I; Hoffman RM
    Biochem Biophys Res Commun; 2023 Feb; 643():48-54. PubMed ID: 36586158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PD-L1 Is Increased by Methionine Restriction Using Recombinant Methioninase in Human Colorectal Cancer Cells.
    Mizuta K; Kang BM; Han Q; Kubota Y; Morinaga S; Sato M; Bouvet M; Tome Y; Nishida K; Hoffman RM
    Cancer Genomics Proteomics; 2024; 21(4):395-398. PubMed ID: 38944421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
    Sato M; Han Q; Mizuta K; Mori R; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    In Vivo; 2024; 38(3):1459-1464. PubMed ID: 38688589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model.
    Masaki N; Han Q; Wu NF; Samonte C; Wu J; Hozumi C; Obara K; Kubota Y; Aoki Y; Miyazaki J; Hoffman RM
    In Vivo; 2022; 36(6):2598-2603. PubMed ID: 36309364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
    Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant-methioninase-producing
    Kubota Y; Han Q; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Diagn Progn; 2023; 3(6):649-654. PubMed ID: 37927811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.